Physician profile
Shaun Kaiser
NPI 1538327150
$4,565.71
in general payments reported to CMS, 2019-2025
27 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $882 · 2020: $323 · 2021: $611 · 2022: $680 · 2023: $1,005 · 2024: $653 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,068.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $583.52 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $392.85 | 2022-2024 | |
| Vifor Pharma, INC. | $389.15 | 2019-2023 | Veltassa |
| Akebia Therapeutics INC | $351.81 | 2019-2025 | Vafseo |
| Otsuka America Pharmaceutical, INC. | $270.04 | 2019-2023 | Jynarque |
| Horizon Therapeutics Plc | $264.98 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $214.85 | 2021-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $206.67 | 2021-2025 | |
| Amgen INC. | $170.48 | 2021-2025 | Tavneos, Krystexxa |
| Cormedix INC. | $166.78 | 2024 | Defencath |
| Abbott Laboratories | $159.67 | 2023-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $154.77 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $148.64 | 2022-2023 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $148.05 | 2021-2024 | Terlivaz, Acthar |
| Fresenius USA Marketing, INC. | $146.34 | 2019-2025 | Velphoro, Velphoro, Korsuva |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $141.21 | 2019-2021 | |
| Glaxosmithkline, LLC. | $131.54 | 2020-2023 | |
| Abbvie INC. | $123.46 | 2019 | |
| Dynavax Technologies Corporation | $119.65 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.49 | 2021-2023 | Gattex |
| Ani Pharmaceuticals, INC. | $56.42 | 2024-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.86 | 2024-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $29.95 | 2024 | Ultomiris |
| Vantive US Healthcare LLC | $23.96 | 2025 | Renal - Pd |
| Shire North American Group INC | $22.52 | 2019 | |
| Renalytix Ai, INC. | $21.65 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Scpharmaceuticals INC. | $20.40 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaun Kaiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.